Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Transcarent (PGNY) expanded its Experience Store on October 21, 2025 by adding three women’s health partners — Maven Clinic, Midi Health, and Progyny — to existing partners Carrot and Kindbody, aiming to centralize fertility, family-building, perimenopause and menopause care for Members.
The WayFinding™ generative-AI experience offers single sign-on, consolidated reporting, and measurable outcomes; Transcarent cites 7.6x more referrals to women’s health and a 10–20% increase in point-solution utilization when fragmentation is reduced.
Progyny (Nasdaq: PGNY) announced that CEO Pete Anevski was named a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health on October 7, 2025.
Anevski joins a global community of leaders committed to advocacy, policy, research, innovation, and investment to close care gaps in women’s health. Progyny said Chief Medical Officer Dr. Janet Choi also participated in GAWH workgroups on maternal health and women’s health science. The company said it will engage in Forum platforms and initiatives to promote research and scalable solutions across governments, investors, and industries worldwide.
Progyny (NASDAQ: PGNY), a women's health and family building solutions provider, reported strong Q2 2025 results with revenue of $332.9 million, up 9.5% year-over-year. Excluding a large transitioning client, revenue growth was 18%. The company achieved net income of $17.1 million ($0.19 per diluted share) and Adjusted EBITDA of $57.9 million.
Key metrics include 542 fertility clients (up from 463 YoY), 16,938 ART cycles performed, and 6.74 million average members. The company generated strong cash flow of $55.5 million in Q2 and a record $105.3 million in H1 2025.
Progyny raised its full-year 2025 guidance, projecting revenue of $1.235-1.270 billion (15.1-18.5% growth excluding the transitioning client) and net income of $52.3-58.9 million.
Progyny (Nasdaq: PGNY), a leader in women's health and family building solutions, released a national study revealing significant disparities in workplace health benefits. While 81% of HR leaders claim commitment to women's health, only 52% of working women find their benefits make healthcare affordable.
The research highlights critical gaps: while 83% of women prioritize menopause-related benefits, only 12% report adequate employer support. Additionally, 24% of women abandon using benefits due to complexity, and 83% of women and 88% of employers agree that centralized support would improve effectiveness. The study emphasizes the need for comprehensive women's health programs, as 69% of benefit managers consider these benefits crucial for attracting and retaining younger talent.
Progyny (Nasdaq: PGNY) has announced a strategic partnership with ŌURA, a leading smart ring manufacturer, to enhance women's health monitoring and care from preconception through menopause. The collaboration will integrate ŌURA's wearable technology data into Progyny's healthcare ecosystem starting in early 2026.
The partnership aims to provide comprehensive health tracking capabilities, including sleep patterns, cycle insights, cardiovascular health, and stress levels. This data integration will enable earlier risk identification and support various health goals, particularly in fertility planning and menopause management. The initiative will be available to Progyny's client base, including employers and health plans.
Progyny (NASDAQ: PGNY), a leader in women's health and family building solutions, has secured a new $200 million revolving credit facility maturing on July 1, 2030. The undrawn facility enhances the company's operational and financial flexibility, though there are no immediate plans for its use.
The company anticipates Q2 2025 financial results to exceed previous guidance due to favorable member activity. Revenue, Adjusted net income, and Adjusted EBITDA are expected to surpass the ranges provided in May. Progyny will report detailed Q2 2025 results on August 7, 2025, after market close.
The company maintains its capital priorities, including potential stock repurchases, product portfolio expansion, investments in distribution channels, and strategic acquisitions.
Progyny (NASDAQ: PGNY), a leader in women's health solutions, has announced the addition of pelvic floor therapy to its comprehensive healthcare offerings. The expansion includes partnerships with Origin for in-person and virtual physical therapy, and Hinge Health for digital care solutions.
The initiative addresses a significant healthcare gap, as one in three women experience pelvic floor issues, with 20% requiring surgery. The program aims to provide early intervention and comprehensive care through specialty-trained providers, potentially reducing the $20 billion annual healthcare costs associated with urinary incontinence alone.
Progyny (NASDAQ: PGNY), a leader in women's health and family building solutions, has appointed Elizabeth Bierbower to its Board of Directors. Bierbower brings over 30 years of healthcare industry experience, most recently serving as Chairman and CEO of Friday Health Plans. Her extensive background includes senior leadership roles at Humana, where she served as Segment President, President of the Employer Group Segment, and COO of Specialty Benefits division. She also held key positions at Highmark Blue Cross Blue Shield and Coventry Health Care.
Bierbower currently serves on several boards, including Option Care Health, BlueSprig, Quest Analytics, Paradigm Corp., and Point32Health. CEO Pete Anevski highlighted that her expertise will support Progyny's strategy to deliver increased value to members, clients, and shareholders while expanding reach and impact.
[ "Addition of highly experienced healthcare executive with 30+ years of industry expertise", "Strategic board appointment bringing expertise from major health plans like Humana", "Enhanced governance through director with extensive board experience at healthcare companies" ]Progyny (NASDAQ: PGNY), a leading women's health and family building solutions provider, has strengthened its Medical Advisory Board with two distinguished appointments. Dr. Gloria Richard-Davis from Morehouse School of Medicine and Dr. Whitney Booker from Columbia University join the board, bringing extensive expertise in women's health and reproductive medicine.
Dr. Richard-Davis is double-board certified in OB-GYN and Reproductive Endocrinology and Infertility, with significant experience in menopause care and health equity. Dr. Booker, double-board certified in OB-GYN and Maternal-Fetal Medicine, specializes in high-risk maternal care and prenatal fetal diagnosis, with NIH-funded research focusing on hypertension and cardiovascular disease in pregnancy.